636 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Effective management of Type 2 Diabetes often requires combination therapies to achieve optimal glycemic control and address comorbidities like obesity. CagriSema combines semaglutide (a potent GLP-1 receptor agonist)…
Understanding semaglutide's direct neurological effects in healthy individuals is profoundly important for expanding its therapeutic potential. If this study reveals positive acute cognitive or energy-enhancing effect…
The successful demonstration of feasibility and tolerability could open new avenues for managing obesity in patients with advanced lung disease, potentially improving their quality of life and clinical outcomes. If Se…
Reducing injection site pain is a critical factor for improving patient adherence to long-term therapies like Semaglutide, which is often administered weekly for chronic conditions such as Type 2 Diabetes and Obesity.…
This regulatory post-marketing surveillance study is crucial for gathering real-world evidence on oral semaglutide, complementing data from controlled clinical trials. Such data is vital for understanding how the drug…
This Phase 2 trial is crucial as it explores a novel combination therapy that could significantly advance the treatment landscape for obesity and Type 2 Diabetes. If successful, combining LY3841136 with Tirzepatide co…
This study addresses a critical unmet need for patients with psoriatic arthritis who also struggle with obesity, a common comorbidity that complicates disease management and often reduces the effectiveness of existing…
Understanding the effects of GLP-1 agonist discontinuation is crucial for informing patient care and developing strategies to manage potential rebound effects and improve long-term outcomes. Many patients may need to …
Tirzepatide is already a highly effective treatment for Type II Diabetes and obesity, known for its significant glycemic control and weight loss benefits. The key implication of this study is that if Tirzepatide can d…
This comprehensive review provides a critical, evidence-based framework for clinicians managing Type 2 Diabetes, moving beyond a glucose-centric approach. It underscores the importance of personalized medicine, where …
The findings confirm that metformin's effect on raising `GLP-1` is not a transient phenomenon but a durable, long-term physiological change. This effect is a direct action of the drug, not a secondary result of weight…
While this specific study was terminated without reporting results, the underlying research question remains highly relevant. If completed, positive findings could have highlighted Liraglutide's potential beyond weigh…
If IBI362 demonstrates superior or comparable efficacy with a favorable safety profile against dulaglutide, it could represent a significant advancement in Type 2 Diabetes management. This would provide a new therapeu…
This large-scale registry is crucial for understanding the current state of obesity and Type 2 Diabetes Mellitus management in China, a region with unique dietary and lifestyle factors. The real-world data collected w…
The successful completion of this Phase III trial could establish IBI362 as a novel and effective treatment option for MAFLD, a condition with limited approved pharmacotherapies. Given the high prevalence of MAFLD in …
The successful completion of this early-phase trial is a significant step forward for IBI362, a novel therapeutic candidate for Type 2 Diabetes. This foundational data on its human safety, tolerability, and drug profi…
The successful completion of enrollment for this Phase III trial is a significant milestone in the development of new therapies for NASH and obesity. Given the limited treatment options for NASH, a condition affecting…
This Phase 1 study is crucial for the continued development of survodutide, as it provides foundational data on how the drug behaves in a specific ethnic population. Understanding the pharmacokinetics and safety profi…
While this specific study did not yield data, the initial intent highlights a critical area of need: understanding how combination therapies like IDegLira perform in real-world settings for patients whose Type 2 Diabe…
The abstract outlines the study's primary objective to determine the effectiveness and safety of adding GLP-1 agonist therapy to basal insulin. The investigators hypothesized that this combination would lead to statis…
This Phase 3 trial is crucial for optimizing Type 2 Diabetes management by evaluating a potentially simpler, yet effective, treatment option. If IDegLira demonstrates comparable efficacy and a favorable safety profile…
This study provides strong evidence supporting the enhanced efficacy of combining a basal insulin (insulin degludec) with a GLP-1 receptor agonist (liraglutide, a class of drugs that mimic a natural hormone to lower b…
The key implication of this research is the potential for IDegLira to offer a significantly safer and more effective therapeutic option for Type 2 Diabetes patients transitioning from hospital to home. By reducing the…
The successful demonstration of comparability between different CagriSema delivery devices is a critical step for its future availability and patient accessibility. This Phase 3 study aims to ensure that regardless of…
If CagriSema proves effective, it could represent a significant advancement in managing Chronic Kidney Disease in patients with Type 2 Diabetes and obesity, a population with high unmet medical needs. The potential fo…
This foundational Phase 1 study is critically important as it provides the initial human safety and tolerability data for semaglutide, a potent GLP-1 receptor agonist. Establishing a safe dose range in healthy individ…
As this PHASE 4 clinical trial is currently RECRUITING participants, specific findings are not yet available, with an estimated completion date of 2026-07-01. Researchers are meticulously collecting data from an estim…
This completed Phase 1 study represents a critical milestone in the development of NNC0113-6856, providing foundational data on its safety and how it behaves in the human body. Establishing a favorable safety and phar…
Tirzepatide has already demonstrated significant efficacy, and exploring higher or alternative dosing strategies could further optimize patient outcomes by potentially enhancing glycemic control and weight loss. This …
The successful completion of this Phase 3 trial is a significant milestone, as Tirzepatide (a dual GIP and GLP-1 receptor agonist) has already demonstrated robust efficacy in adults with Type 2 Diabetes and obesity. I…
This Phase 3b study represents a significant step towards developing more holistic treatment strategies for complex conditions. If successful, combining Mirikizumab and Tirzepatide could offer a novel therapeutic opti…
Tirzepatide offers a powerful new treatment option for Type 2 Diabetes Mellitus, particularly for those struggling to achieve adequate glycemic control with existing therapies. The successful completion of this Phase …
The first approval of Mazdutide in China is a pivotal development, introducing a novel dual glucagon receptor (GcgR) and glucagon-like peptide-1 receptor (GLP-1R) agonist to the therapeutic landscape. This provides a …
This case report provides crucial preliminary evidence supporting the potential of Mazdutide as a comprehensive treatment option for adolescents grappling with the complex interplay of obesity, type 2 diabetes, and hy…